A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Trial Profile

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Phase of Trial: Phase I

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs Bb 2121 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man
  • Sponsors bluebird bio; Celgene Corporation
  • Most Recent Events

    • 13 Sep 2017 According to bluebird bio media release, first patient has been treated for part B expansion cohort study of the trial.
    • 25 Jun 2017 Updated results (n=11;data cut off: 18 Nov 2016) assessing safety and preliminary efficacy presented at the 22nd Congress of the European Haematology Association.
    • 19 Jun 2017 According to a Celgene Corporation media release, data from this trial will be presented at the 22nd European Hematology Association annual meeting 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top